Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Amneal Pharmaceuticals has reported Acquisitions for 3 years, with the latest figure at $72.7 million in Q4 2021.

• On a quarterly basis, Acquisitions changed N/A year-over-year to $72.7 million in Q4 2021; TTM through Dec 2022 was $72.7 million, a 50.38% decrease from a year earlier, with the FY2022 full-year figure at $84.7 million, down 42.19% from the prior year.
• Acquisitions was $72.7 million for Q4 2021 at Amneal Pharmaceuticals, down from $73.8 million in the prior quarter.
• The five-year high for Acquisitions was $253.6 million in Q1 2020, with the low at -$2.6 million in Q3 2020.
• Average Acquisitions over 3 years is $66.9 million, with a median of $38.0 million recorded in 2018.
• The largest YoY upside for Acquisitions was 19587.47% in 2021 against a maximum downside of 19587.47% in 2021.
• Over 3 years, Acquisitions stood at $3.3 million in 2018, then slumped by 179.76% to -$2.6 million in 2020, then soared by 2854.36% to $72.7 million in 2021.
• The last three Acquisitions figures came in at $72.7 million (Q4 2021), $73.8 million (Q2 2021), and -$2.6 million (Q3 2020), per Business Quant data.